Dr Agarwal’s Health Care Ltd, a leading eye care service provider, posted a consolidated profit after tax (PAT) of ₹28.24 crore for the third quarter ended December 31, 2024, marking a 25 per cent year-on-year (YoY) increase from ₹22.59 crore in the same quarter last year.

The company’s revenue from operations surged 29 per cent YoY to ₹431 crore, up from ₹333 crore, driven by strong performance across its facilities. Revenue from operations in India grew by 34.5 per cent to ₹390 crore, while revenue from mature facilities increased by 16.6 per cent YoY to ₹291 crore. EBITDA rose by 26.3 per cent YoY to ₹128 crore, with an EBITDA margin of 28.8 per cent, according to a company statement.

Dr Agarwal’s Health Care continued its expansion during the quarter, adding 12 new facilities, bringing its total network to 221 as of December 31, 2024.

For the nine months of FY2025, the company reported a PAT of ₹68 crore, a 26.2 per cent YoY increase, with a PAT margin of 5.3 per cent. Revenue from operations for the period stood at ₹1,251 crore, reflecting a 27.2 per cent YoY growth. The Indian operations contributed ₹1,124 crore, up 31.7 per cent YoY, while revenue from mature facilities grew by 15 per cent to ₹874 crore. EBITDA for the nine months stood at ₹356 crore, up 27.5 per cent, with an EBITDA margin of 27.8 per cent.

During this period, the company added 42 new facilities—35 newly established and seven acquired—and performed 213,602 surgeries, registering a 31.8 per cent YoY increase.

Commenting on the company’s maiden quarter performance post-listing, Dr Adil Agarwal, CEO of Dr Agarwal’s Health Care Ltd, said: “We have delivered a robust 29.5 per cent growth in revenue and 26.3 per cent in EBITDA in our maiden quarter post listing. Strong patient footfalls and increased surgeries have driven our performance. While we continue our growth trajectory, we remain committed to sustainable and steady expansion in the coming quarters.”

Published on February 14, 2025